- Home
- NLSP vs CHNR Comparison
NLSP vs CHNR Comparison
Compare NLSP & CHNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NLSP
- CHNR
- Stock Information
- Founded
- NLSP 2015
- CHNR N/A
- Country
- NLSP Switzerland
- CHNR Hong Kong
- Employees
- NLSP N/A
- CHNR N/A
- Industry
- NLSP Biotechnology: Pharmaceutical Preparations
- CHNR Precious Metals
- Sector
- NLSP Health Care
- CHNR Basic Materials
- Exchange
- NLSP Nasdaq
- CHNR Nasdaq
- Market Cap
- NLSP 5.2M
- CHNR 6.0M
- IPO Year
- NLSP 2021
- CHNR 1995
- Fundamental
- Price
- NLSP $1.99
- CHNR $0.56
- Analyst Decision
- NLSP
- CHNR
- Analyst Count
- NLSP 0
- CHNR 0
- Target Price
- NLSP N/A
- CHNR N/A
- AVG Volume (30 Days)
- NLSP 535.3K
- CHNR 53.5K
- Earning Date
- NLSP 12-31-2024
- CHNR 01-01-0001
- Dividend Yield
- NLSP N/A
- CHNR N/A
- EPS Growth
- NLSP N/A
- CHNR N/A
- EPS
- NLSP N/A
- CHNR N/A
- Revenue
- NLSP N/A
- CHNR N/A
- Revenue This Year
- NLSP N/A
- CHNR N/A
- Revenue Next Year
- NLSP N/A
- CHNR N/A
- P/E Ratio
- NLSP N/A
- CHNR N/A
- Revenue Growth
- NLSP N/A
- CHNR N/A
- 52 Week Low
- NLSP $1.73
- CHNR $0.51
- 52 Week High
- NLSP $24.32
- CHNR $8.85
- Technical
- Relative Strength Index (RSI)
- NLSP 33.52
- CHNR 37.42
- Support Level
- NLSP $1.78
- CHNR $0.54
- Resistance Level
- NLSP $2.79
- CHNR $0.77
- Average True Range (ATR)
- NLSP 0.33
- CHNR 0.04
- MACD
- NLSP 0.04
- CHNR -0.00
- Stochastic Oscillator
- NLSP 11.77
- CHNR 15.63
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd is a biopharmaceutical company. It is engaged in the discovery and development of life-improving drug therapies to treat rare and complex CNS disorders. It focuses on developing therapeutics for the treatment of neurobehavioral and neurocognitive disorders. The company's tangible assets are held in the United States. Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.
About CHNR China Natural Resources Inc.
China Natural Resources Inc is an investment holding company. It principally engaged in the exploration and mining and wastewater treatment businesses in the People's Republic of China. The company has two operating segments: (i) Wastewater treatment segment, which consists of sales of assembled equipment, provision of construction service, and participation in PPP projects as an operator (ii) Exploration and mining segment, which consists of the exploration of lead, silver, and other metals in the Inner Mongolia Autonomous Region of the PRC and the trading of copper ores products. It earns the majority of its revenue from the Wastewater treatment segment.